Concepts (125)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Cowpox virus | 3 | 2018 | 19 | 0.54 | Why? |
| Germany | 8 | 2021 | 9196 | 0.23 | Why? |
| Proteomics | 3 | 2021 | 2481 | 0.22 | Why? |
| Organisation for Economic Co-Operation and Development | 1 | 2021 | 69 | 0.22 | Why? |
| Virion | 3 | 2018 | 1444 | 0.21 | Why? |
| Clostridium botulinum type A | 1 | 2017 | 1 | 0.18 | Why? |
| Herpesvirus 4, Human | 1 | 2001 | 387 | 0.18 | Why? |
| Botulism | 1 | 2017 | 18 | 0.18 | Why? |
| Viral Core Proteins | 1 | 2018 | 134 | 0.17 | Why? |
| Epstein-Barr Virus Infections | 1 | 2001 | 366 | 0.17 | Why? |
| Proteasome Endopeptidase Complex | 1 | 2018 | 249 | 0.16 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.16 | Why? |
| Ubiquitination | 1 | 2018 | 343 | 0.16 | Why? |
| Lassa Fever | 1 | 2017 | 88 | 0.16 | Why? |
| Virology | 1 | 2020 | 489 | 0.16 | Why? |
| Immunoglobulins | 1 | 2001 | 811 | 0.15 | Why? |
| Botulinum Toxins, Type A | 1 | 2017 | 134 | 0.15 | Why? |
| Mass Spectrometry | 1 | 2020 | 1165 | 0.14 | Why? |
| Adaptation, Physiological | 1 | 2017 | 359 | 0.14 | Why? |
| Viral Proteins | 4 | 2021 | 7370 | 0.13 | Why? |
| Coronavirus OC43, Human | 1 | 2021 | 1157 | 0.13 | Why? |
| Coronavirus 229E, Human | 1 | 2021 | 1241 | 0.12 | Why? |
| High-Throughput Nucleotide Sequencing | 3 | 2021 | 3633 | 0.12 | Why? |
| Enzyme-Linked Immunosorbent Assay | 2 | 2020 | 7868 | 0.09 | Why? |
| Polymerase Chain Reaction | 2 | 2020 | 6740 | 0.09 | Why? |
| Point-of-Care Systems | 1 | 2021 | 2955 | 0.08 | Why? |
| Proteome | 1 | 2017 | 1812 | 0.08 | Why? |
| Disease Outbreaks | 4 | 2020 | 27595 | 0.08 | Why? |
| Pharmaceutical Preparations | 1 | 2021 | 1897 | 0.08 | Why? |
| Real-Time Polymerase Chain Reaction | 3 | 2021 | 11367 | 0.08 | Why? |
| Pandemics | 7 | 2021 | 389249 | 0.08 | Why? |
| Contact Tracing | 2 | 2017 | 8448 | 0.07 | Why? |
| Molecular Diagnostic Techniques | 1 | 2021 | 4239 | 0.07 | Why? |
| Antigens, Viral | 1 | 2001 | 6298 | 0.07 | Why? |
| Tertiary Care Centers | 1 | 2020 | 8248 | 0.06 | Why? |
| Australasia | 1 | 2021 | 89 | 0.06 | Why? |
| Travel | 2 | 2017 | 7220 | 0.05 | Why? |
| Coronavirus | 3 | 2020 | 18339 | 0.05 | Why? |
| Quarantine | 3 | 2021 | 18418 | 0.05 | Why? |
| Polyubiquitin | 1 | 2018 | 14 | 0.05 | Why? |
| Masks | 1 | 2021 | 8528 | 0.05 | Why? |
| Immunomodulation | 2 | 2017 | 1472 | 0.05 | Why? |
| Polyproteins | 1 | 2021 | 814 | 0.04 | Why? |
| Togo | 1 | 2017 | 95 | 0.04 | Why? |
| Peptide Library | 1 | 2021 | 564 | 0.04 | Why? |
| DNA Replication | 1 | 2018 | 121 | 0.04 | Why? |
| Amino Acid Sequence | 2 | 2021 | 6049 | 0.04 | Why? |
| Slovakia | 1 | 2017 | 135 | 0.04 | Why? |
| Humans | 18 | 2021 | 930598 | 0.04 | Why? |
| Virus Activation | 1 | 2001 | 480 | 0.04 | Why? |
| Antibody Specificity | 1 | 2001 | 1328 | 0.04 | Why? |
| DNA-Directed RNA Polymerases | 1 | 2017 | 239 | 0.04 | Why? |
| North America | 1 | 2021 | 1400 | 0.04 | Why? |
| State Government | 1 | 2021 | 416 | 0.04 | Why? |
| Czech Republic | 1 | 2017 | 307 | 0.04 | Why? |
| Sensitivity and Specificity | 3 | 2021 | 22971 | 0.04 | Why? |
| Ubiquitin | 1 | 2018 | 243 | 0.04 | Why? |
| Rats, Wistar | 1 | 2017 | 621 | 0.04 | Why? |
| Genetic Fitness | 1 | 2017 | 339 | 0.04 | Why? |
| Genome, Viral | 1 | 2017 | 13157 | 0.04 | Why? |
| Tandem Mass Spectrometry | 1 | 2021 | 1031 | 0.04 | Why? |
| Public Health | 1 | 2021 | 16359 | 0.04 | Why? |
| Virus Cultivation | 1 | 2017 | 579 | 0.03 | Why? |
| HeLa Cells | 1 | 2018 | 1303 | 0.03 | Why? |
| Asia | 1 | 2021 | 2399 | 0.03 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.03 | Why? |
| Respiratory Tract Infections | 1 | 2014 | 6817 | 0.03 | Why? |
| Limit of Detection | 1 | 2021 | 2698 | 0.03 | Why? |
| Host Specificity | 1 | 2017 | 926 | 0.03 | Why? |
| Coronavirus Infections | 5 | 2020 | 253789 | 0.03 | Why? |
| Fluorescent Antibody Technique, Indirect | 1 | 2013 | 393 | 0.03 | Why? |
| Cross Infection | 1 | 2014 | 8675 | 0.03 | Why? |
| United Arab Emirates | 1 | 2014 | 704 | 0.03 | Why? |
| Transcription, Genetic | 1 | 2017 | 1326 | 0.03 | Why? |
| Infection Control | 2 | 2017 | 23131 | 0.03 | Why? |
| Qatar | 1 | 2013 | 784 | 0.03 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2013 | 9706 | 0.03 | Why? |
| RNA | 1 | 2017 | 1278 | 0.03 | Why? |
| Rats | 1 | 2017 | 2764 | 0.02 | Why? |
| Immunoglobulin A | 1 | 2001 | 3567 | 0.02 | Why? |
| Risk Management | 1 | 2017 | 1044 | 0.02 | Why? |
| Cell Line, Tumor | 1 | 2018 | 3608 | 0.02 | Why? |
| Syndrome | 1 | 2014 | 1310 | 0.02 | Why? |
| Antibodies, Viral | 1 | 2001 | 51949 | 0.02 | Why? |
| Peptides | 1 | 2021 | 2513 | 0.02 | Why? |
| Sequence Analysis, DNA | 1 | 2017 | 2830 | 0.02 | Why? |
| Pneumonia, Viral | 3 | 2020 | 243684 | 0.02 | Why? |
| Immunoglobulin G | 2 | 2020 | 21571 | 0.02 | Why? |
| Disease Notification | 1 | 2013 | 639 | 0.02 | Why? |
| Serologic Tests | 1 | 2020 | 4359 | 0.02 | Why? |
| Longitudinal Studies | 1 | 2021 | 9893 | 0.02 | Why? |
| Camelus | 1 | 2014 | 1425 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2017 | 4020 | 0.02 | Why? |
| Seroepidemiologic Studies | 1 | 2020 | 10017 | 0.02 | Why? |
| Reproducibility of Results | 1 | 2021 | 11304 | 0.02 | Why? |
| Europe | 1 | 2021 | 12702 | 0.02 | Why? |
| Immunoglobulin M | 1 | 2001 | 9091 | 0.02 | Why? |
| Clinical Laboratory Techniques | 2 | 2021 | 23402 | 0.02 | Why? |
| Population Surveillance | 1 | 2020 | 4967 | 0.02 | Why? |
| Virus Diseases | 1 | 2020 | 3779 | 0.02 | Why? |
| Delayed Diagnosis | 1 | 2013 | 1529 | 0.02 | Why? |
| Animals | 3 | 2017 | 78931 | 0.02 | Why? |
| Cell Line | 1 | 2017 | 12040 | 0.01 | Why? |
| Neutralization Tests | 1 | 2013 | 6698 | 0.01 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.01 | Why? |
| Phylogeny | 1 | 2017 | 13341 | 0.01 | Why? |
| Infant | 1 | 2001 | 30274 | 0.01 | Why? |
| Incidence | 1 | 2020 | 25622 | 0.01 | Why? |
| Child, Preschool | 1 | 2001 | 36283 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2017 | 11041 | 0.01 | Why? |
| Virus Replication | 1 | 2017 | 14331 | 0.01 | Why? |
| Male | 4 | 2020 | 367725 | 0.01 | Why? |
| Middle Aged | 3 | 2020 | 270681 | 0.01 | Why? |
| Occupational Exposure | 1 | 2013 | 4742 | 0.01 | Why? |
| Child | 1 | 2001 | 70012 | 0.01 | Why? |
| Female | 3 | 2020 | 380317 | 0.01 | Why? |
| Aged | 2 | 2020 | 215776 | 0.01 | Why? |
| Adolescent | 1 | 2020 | 86841 | 0.01 | Why? |
| Adult | 2 | 2020 | 244371 | 0.01 | Why? |
| Risk Assessment | 1 | 2013 | 25439 | 0.01 | Why? |
| Treatment Outcome | 1 | 2013 | 51732 | 0.00 | Why? |
| Surveys and Questionnaires | 1 | 2013 | 43792 | 0.00 | Why? |
| Risk Factors | 1 | 2013 | 71621 | 0.00 | Why? |
| Health Personnel | 1 | 2013 | 29646 | 0.00 | Why? |
| Retrospective Studies | 1 | 2013 | 105322 | 0.00 | Why? |
Schaade's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(125)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(81)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_